Competact

Competact is a combination oral antidiabetic medicine used to treat type 2 diabetes mellitus in adults. Each tablet contains two active ingredients: pioglitazone and metformin hydrochloride. It is prescribed when treatment with metformin alone, or with pioglitazone alone, has not provided adequate blood glucose control, or as a convenient alternative for patients who are already stabilised on both medicines taken separately. Competact is always used alongside dietary measures and exercise as part of a comprehensive diabetes management plan.

How Competact Works

Pioglitazone belongs to the thiazolidinedione (TZD) class of antidiabetic medicines. It acts as a selective agonist of the peroxisome proliferator-activated receptor gamma (PPAR-gamma), a nuclear receptor found predominantly in adipose tissue. Activation of this receptor improves insulin sensitivity in peripheral tissues, particularly fat and muscle, reducing the amount of insulin required to achieve normal blood glucose levels. Pioglitazone also has modest favourable effects on lipid profiles, typically lowering triglycerides and raising HDL cholesterol.

Metformin hydrochloride is a biguanide that primarily works by reducing hepatic glucose production (gluconeogenesis). It also improves insulin sensitivity in peripheral tissues and reduces intestinal glucose absorption. Metformin does not stimulate insulin secretion and therefore carries a very low risk of hypoglycaemia when used alone.

Why Combination Treatment?

The two agents in Competact target different pathways in the development of insulin resistance and hyperglycaemia, providing complementary effects. Clinical studies have shown that this combination achieves superior HbA1c reductions compared with either agent alone. Because both ingredients work through insulin-sensitising rather than insulin-secreting mechanisms, the risk of hypoglycaemia remains low when Competact is used without sulphonylureas or insulin. Competact is not suitable for type 1 diabetes.

Competact is indicated as an oral antidiabetic treatment in adults with type 2 diabetes, particularly those with obesity or significant insulin resistance who have not achieved adequate glycaemic control on metformin monotherapy, or who are already taking pioglitazone and metformin as separate tablets and wish to simplify their regimen.

How to Take Competact

Competact tablets should be taken twice daily with or just after meals to reduce the risk of gastrointestinal side effects associated with metformin. Swallow the tablets whole with a glass of water. Consistent timing and adherence are important for maintaining stable blood glucose levels throughout the day. Patients who miss a dose should take it as soon as they remember with food, unless it is almost time for their next scheduled dose.

Monitoring and Review

Regular blood glucose monitoring, HbA1c measurement (typically every three to six months initially, then every six months once stable), and kidney function tests are essential during treatment with Competact. Because metformin is renally cleared, it must be withheld or discontinued if renal function deteriorates significantly (eGFR below 30 mL/min/1.73 m2). Liver function should be monitored periodically given the rare risk of hepatotoxicity with pioglitazone. Patients should be educated to recognise symptoms that may indicate fluid retention, such as ankle swelling and breathlessness, and to seek medical attention promptly if these occur.

The dose of Competact is determined by the individual patient's existing pioglitazone and metformin doses, or by the prescribing clinician based on renal function, glycaemic targets, and tolerability. The usual starting dose for patients switching from separate tablets is one tablet of the appropriate strength twice daily, taken with meals.

The pioglitazone component should not exceed 45 mg per day in total. The metformin component is typically dosed at 850 mg twice daily, with the option to increase in some formulations. No dose adjustment is generally needed in elderly patients based on age alone, but renal function should be assessed before and regularly during treatment, as metformin accumulation in renal impairment carries a small risk of lactic acidosis.

Competact should be temporarily discontinued before procedures involving iodinated contrast media and in situations of serious illness, dehydration, or surgery, to reduce the risk of metformin-associated lactic acidosis. It should be restarted only once renal function has been confirmed to be stable.

Competact may cause a range of side effects. Many are associated with the individual components, and understanding which ingredient is responsible can help guide management decisions.

Common Side Effects

• Gastrointestinal effects (primarily from metformin): nausea, vomiting, diarrhoea, abdominal discomfort, and loss of appetite, particularly when initiating treatment or increasing the dose; taking the tablet with food usually helps
• Fluid retention and oedema: swelling of the ankles or legs is a recognised effect of pioglitazone and may worsen pre-existing heart conditions
• Weight gain: pioglitazone is associated with modest increases in body weight due to fluid retention and fat redistribution
• Hypoglycaemia: low risk when Competact is used alone, but risk increases significantly if it is combined with sulphonylureas or insulin
• Headache and dizziness

Serious Side Effects

Patients should seek urgent medical attention for:

• Heart failure: pioglitazone can cause or worsen heart failure due to fluid retention; breathlessness, rapid weight gain, and ankle swelling are warning signs
• Bladder cancer: long-term use of pioglitazone (more than one year) has been associated with a small increased risk of bladder cancer; any unexplained haematuria (blood in urine) should be investigated promptly
• Lactic acidosis: rare but potentially fatal accumulation of lactic acid, primarily associated with metformin in patients with renal impairment, liver disease, or severe dehydration
• Hepatotoxicity: rare cases of liver injury associated with pioglitazone; jaundice, dark urine, or unexplained fatigue warrant liver function testing
• Bone fractures: pioglitazone has been associated with increased fracture risk in women

Competact carries a number of important safety warnings that should be considered before and during treatment.

Cardiovascular and Fluid Retention Risk

Pioglitazone must not be used in patients with existing or a history of heart failure. Fluid retention is a recognised class effect of thiazolidinediones and can precipitate or worsen cardiac decompensation. Patients should be monitored regularly for signs of fluid overload, particularly in those with pre-existing cardiovascular risk factors, mild cardiac dysfunction, or peripheral oedema. Any new or worsening respiratory symptoms or lower limb swelling should prompt urgent clinical review.

Bladder Cancer and Long-Term Use

Epidemiological data and clinical trials have suggested a small but statistically increased risk of bladder cancer in patients taking pioglitazone for more than 12 months. Competact should not be prescribed for patients with active or a history of bladder cancer. Unexplained haematuria during treatment should be investigated without delay. This risk must be discussed with patients as part of the informed consent process.

Competact should also be used with caution in patients with active liver disease, as both metformin and pioglitazone may affect hepatic function. Alcohol intake should be minimised during treatment with metformin due to the risk of lactic acidosis. Patients travelling to areas where access to regular meals may be disrupted should be counselled on managing their medication during such periods.

Competact must not be used in the following situations:

• Type 1 diabetes mellitus or diabetic ketoacidosis
• Known hypersensitivity to pioglitazone, metformin, or any excipients
• Renal impairment with eGFR below 30 mL/min/1.73 m2 (metformin component)
• Hepatic impairment or elevated liver enzymes (more than three times the upper limit of normal)
• Current or previous heart failure (NYHA Class I-IV)
• History of or active bladder cancer
• Pregnancy and breastfeeding
• Acute or chronic conditions that may cause tissue hypoxia (e.g., respiratory failure, severe infection, shock), due to lactic acidosis risk with metformin
• Excessive alcohol consumption
• Use of iodinated contrast agents (metformin must be withheld peri-procedure)